Related Experiment Video
Updated: May 18, 2026
Phenotypic Analysis and Isolation of Murine Hematopoietic Stem Cells and Lineage-committed Progenitors
Published on: July 8, 2012
[Immunophenotypic analysis of hematogones in patients with hematological malignancies]
Shoichi Kobayashi1, Risa Kumagai, Akiko Omiya
1Division of Clinical Laboratory, Kanagawa Cancer Center, Japan.
Insights
Hematogones, immature B-cell precursors, were frequently detected in patients with hematologic malignancies using flow cytometry. This study identified novel immunophenotypes, suggesting their appearance is common in these conditions.
Area of Science:
- Hematology
- Immunology
- Flow Cytometry
Context:
- Hematogones are immature B-cell precursors.
- Their presence in hematologic malignancies requires further characterization.
- Flow cytometry is a key technique for immunophenotypic analysis.
Purpose:
- To investigate the immunophenotypic characteristics of hematogones in patients with hematologic malignancies.
- To determine the frequency and diagnostic significance of hematogones in acute leukemia, myelodysplastic syndromes, and malignant lymphoma.
Summary:
- A total of 102 specimens from 93 patients were analyzed.
- Hematogones were detected in 55 specimens, particularly in acute myeloid leukemia in remission and B-cell lymphoma.
- Distinct stages (1, 2/3, intermediate) and CD45 expression patterns were identified, revealing potentially unreported immunophenotypes.
Impact:
- Findings suggest hematogones are frequently observed in hematologic malignancies.
- The study highlights the potential for novel hematogone immunophenotypes.
- This research contributes to a better understanding of hematogone behavior in disease states.
Abstract:
We studied immunophenotypic analysis of hematogones by flow cytometry. A total of 102 specimens from 93 patients with acute leukemia (52 specimens), myelodysplastic syndromes (4), or malignant lymphoma (46) were analyzed between April and August, 2011. Hematogones were detected in 55 specimens and highly identified in patients with acute myeloid leukemia in remission and B cell lymphoma. Stage 1 (CD34(+)CD20(-)) and stage 2/3 (CD34(-)CD20(+)) were detected in 9.9% and 52.7%, respectively. In addition, the intermediate type (CD34(+)CD20(+)) was identified in 37.4%. All specimens of stage 3 in bright CD45 expression were positive for CD5 and included CD5(+)CD23(-)CD11c(-), 11.1%, CD5(+)CD23(+)CD11c(-), 85.2%, and CD5(+)CD23(+)CD11c(+), 3.7%. These findings suggest that hematogones with unreported immunophenotypes may exist and the appearance of hematogones in hematologic malignancies may be relatively frequent.
More Related Videos
14:30Immunophenotyping and Cell Sorting of Human MKs from Human Primary Sources or Differentiated In Vitro from Hematopoietic Progenitors
Published on: August 7, 2021
12:36Single-cell Analysis of Immunophenotype and Cytokine Production in Peripheral Whole Blood via Mass Cytometry
Published on: June 26, 2018